Rivaroxaban 20 mg daily and adjusted-dose warfarin were compared in patients with nonvalvular AF in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET-AF) [52]. This evidence concerns the gene F10 and atrial fibrillation.